Angiodynamics (ANGO) Research & Development (2010 - 2026)

Angiodynamics (ANGO) has reported Research & Development for 17 consecutive years, with $31.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 17.73% year-over-year to $31.1 million; the trailing twelve-month figure through May 2026 stood at $113.4 million (up 9.95% YoY), and the FY2026 full-year result was $113.4 million, up 9.95% from the prior year.
• Research & Development advanced to $31.1 million in Q2 2026 per ANGO's latest filing, from $27.4 million in the prior quarter.
• Across five years, Research & Development topped out at $31.1 million in Q2 2026 and bottomed at $20.4 million in Q1 2022.
• Historically, Research & Development has averaged $26.2 million across 5 years, with a median of $26.2 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Research & Development climbed 24.44% in 2023, then declined 6.51% in 2024.
• Over 5 years, Research & Development stood at $26.0 million in 2022, then declined by 2.09% to $25.5 million in 2023, then climbed by 0.49% to $25.6 million in 2024, then increased by 4.38% to $26.7 million in 2025, then gained by 16.52% to $31.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $31.1 million, $27.4 million, and $26.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.